Hepatitis B virus-associated glomerulonephritis Medical Services in China

Hepatitis B virus-associated glomerulonephritis (HBV-GN) is a rare but clinically significant immune-complex-mediated kidney disease triggered by chronic hepatitis B virus (HBV) infection. It predominantly manifests as membranous nephropathy (MN) or, less commonly, membranoproliferative glomerulonephritis (MPGN), characterized by HBV antigen deposition—particularly hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg)—within the glomerular basement membrane and mesangium. Pathogenesis involves persistent viral replication leading to formation of circulating immune complexes that deposit in renal tissue, activating complement cascades and inducing podocyte injury, proteinuria, and progressive glomerular damage. Unlike primary glomerulonephritis, HBV-GN is directly linked to virological activity and host immune dysregulation; antiviral therapy often reverses histopathological changes, underscoring its unique treatability among secondary GN etiologies. Epidemiologically, HBV-GN is endemic in regions with high HBV prevalence—including East Asia, sub-Saharan Africa, and parts of Latin America—with an estimated incidence of 1–5% among chronically HBV-infected adults presenting with nephrotic syndrome. In China, where chronic HBV carriage affects ~5–7% of the population, HBV-GN accounts for up to 30% of pediatric nephrotic syndrome cases and ~10–15% of adult-onset membranous nephropathy. Key risk factors include childhood HBV acquisition (vertical transmission), HBeAg positivity, high serum HBV DNA load (>2,000 IU/mL), male sex, and genetic susceptibility (e.g., HLA-DRB1*07 and *09 alleles). Notably, immunosuppressants like corticosteroids alone may exacerbate viral replication and are contraindicated without concurrent antiviral coverage. Quality of life impact is substantial: patients frequently experience fatigue, edema, recurrent infections, and psychological distress due to chronic illness, dietary restrictions, and treatment burden. Proteinuria and hypoalbuminemia increase thromboembolic and cardiovascular risks, while delayed diagnosis can lead to irreversible fibrosis and progression to end-stage kidney disease (ESKD). Early recognition—via serologic HBV screening in all glomerulonephritis patients, especially in endemic areas—is critical. With timely antiviral-based regimens, over 70% achieve complete or partial remission of proteinuria within 6–12 months, preserving long-term renal function and markedly improving functional status and mental well-being.

Hepatitis B virus-associated glomerulonephritis (HBV-GN) is an immune-complex-mediated renal disease occurring predominantly in chronic HBV carriers, especially children and young adults in endemic regions. It represents a systemic manifestation of persistent HBV infection, wherein viral antigens—particularly hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg)—deposit in the glomerular basement membrane and mesangium, triggering complement activation and inflammatory cell recruitment. The most common histopathological pattern is membranous nephropathy (MN), accounting for approximately 70–80% of biopsy-proven cases; less frequently, membranoproliferative glomerulonephritis (MPGN), IgA-dominant proliferative GN, or minimal change disease may be observed. The pathogenesis centers on in situ immune complex formation: circulating HBsAg–anti-HBs immune complexes deposit in subepithelial locations (in MN) or subendothelial/mesangial sites (in MPGN), leading to podocyte injury, proteinuria, and progressive glomerular damage.

Common causes include persistent HBV replication with high serum levels of HBeAg and HBsAg, particularly in the immune-tolerant or immune-active phases of chronic infection. Viral integration into host hepatocyte DNA and aberrant expression of HBV-encoded proteins (e.g., HBx) may further dysregulate immune signaling and promote autoantibody generation. Notably, HBV-GN rarely develops in immunocompetent adults with resolved or inactive infection; it is strongly associated with chronicity established early in life—especially perinatal or early childhood acquisition—where immune tolerance permits unchecked viral replication and prolonged antigenemia.

Triggers encompass acute HBV reactivation (e.g., following immunosuppression or chemotherapy), initiation of interferon-alpha therapy (which can transiently exacerbate immune complex deposition), or intercurrent infections that amplify systemic inflammation and alter immune complex clearance. Vaccination against HBV does not trigger HBV-GN; rather, it is protective. Conversely, failure to vaccinate in infancy—particularly in high-prevalence settings—is a critical modifiable trigger for subsequent development.

Risk factors are multifactorial. Age at infection is paramount: vertical transmission confers the highest risk, with up to 90% of neonates developing chronic infection versus <5% of immunocompetent adults. Geographic endemicity (e.g., East Asia, Sub-Saharan Africa, parts of South America) correlates strongly with incidence due to higher rates of perinatal transmission and limited access to universal infant vaccination. Male sex is consistently associated with increased susceptibility and more severe renal involvement, possibly due to hormonal modulation of immune responses and HBV replication. Prolonged duration of chronic HBV infection (>10 years), high baseline HBV DNA load (>2,000 IU/mL), and persistent HBeAg positivity significantly elevate risk. Concomitant conditions such as HIV co-infection impair immune surveillance and accelerate HBV-related renal injury. Additionally, untreated or inadequately suppressed HBV increases cumulative antigen exposure and immune complex burden.

Genetic factors contribute to interindividual variability in susceptibility and phenotype. Polymorphisms in HLA class II alleles—including HLA-DRB1*07 and HLA-DQB1*02—have been linked to increased risk of HBV-GN in Asian cohorts, likely by influencing antigen presentation and T-cell–dependent B-cell activation against HBV antigens. Variants in genes encoding Fcγ receptors (e.g., FCGR2A-H131R) affect immune complex phagocytosis efficiency, while polymorphisms in complement regulatory proteins (e.g., CFH, CD46) may predispose to uncontrolled complement activation in glomeruli. Genome-wide association studies suggest additional loci involved in B-cell differentiation and interferon signaling pathways, though validation across diverse ethnic populations remains incomplete.

Environmental factors include socioeconomic determinants: limited healthcare access delays diagnosis of chronic HBV and initiation of antiviral therapy; overcrowded living conditions facilitate horizontal transmission in early childhood; and lack of universal birth-dose HBV vaccination programs perpetuates vertical transmission cycles. Iatrogenic exposures—such as repeated blood transfusions before routine HBV screening or unsafe injection practices—remain relevant in resource-limited settings. Importantly, environmental toxins (e.g., heavy metals, organic solvents) are not established contributors to HBV-GN, distinguishing it from other forms of secondary GN. Public health interventions targeting maternal HBsAg screening, timely infant HBV vaccination (including birth dose), and antiviral prophylaxis for high-risk newborns constitute the most effective preventive strategies.

Hepatitis B virus-associated glomerulonephritis (HBV-GN) is an immune-complex–mediated renal disease occurring predominantly in children and young adults, especially in endemic HBV regions such as East Asia and sub-Saharan Africa. It arises from deposition of hepatitis B surface antigen (HBsAg)-containing immune complexes in the glomerular basement membrane and mesangium, triggering complement activation, inflammatory cell infiltration, and progressive glomerular injury. Unlike primary glomerulonephritides, HBV-GN is etiologically linked to chronic or persistent HBV infection—most commonly with HBeAg positivity—and often manifests independently of overt hepatic dysfunction.

Early symptoms are frequently subtle or entirely absent. Patients may remain asymptomatic for months to years despite active viral replication and early histopathologic changes. When present, early manifestations typically reflect mild nephrotic-range or subnephrotic proteinuria (often detected incidentally on urinalysis), microscopic hematuria, and occasionally mild peripheral edema—particularly periorbital swelling upon waking. Hypertension is uncommon at this stage, and serum creatinine usually remains within normal limits. Some patients report nonspecific constitutional symptoms including fatigue, low-grade fever, or arthralgias, which may be misattributed to viral prodrome or systemic inflammation. Importantly, liver enzyme elevations (ALT/AST) are often minimal or absent; thus, absence of hepatomegaly or jaundice does not exclude HBV-GN.

Typical symptoms emerge as glomerular injury progresses and correlate with the predominant histopathologic pattern—most frequently membranous nephropathy (MN), followed by membranoproliferative glomerulonephritis (MPGN) and IgA-dominant mesangial proliferative GN. Nephrotic syndrome is the hallmark clinical presentation: heavy proteinuria (>3.5 g/24 h), hypoalbuminemia (<30 g/L), hyperlipidemia, and generalized edema—including dependent edema (ankles, sacrum), ascites, and pleural effusions in severe cases. Gross hematuria is rare but may occur during acute exacerbations, particularly in MPGN variants. Patients often develop frothy urine due to marked proteinuria and may report weight gain attributable to fluid retention. Hypertension becomes more prevalent as renal function declines, reflecting both volume overload and renin-angiotensin system activation.

Accompanying symptoms reflect extra-renal immune complex deposition and systemic immune dysregulation. Cutaneous vasculitis—such as palpable purpura—may appear, especially in MPGN-type disease. Arthralgias and myalgias are common, sometimes mimicking polyarteritis nodosa. Less frequently, patients exhibit cryoglobulinemia-related phenomena including Raynaud’s phenomenon, digital ulceration, or neuropathy. In children, growth retardation and delayed puberty may signal chronic protein loss and malnutrition. Mild hepatosplenomegaly can occur without biochemical evidence of cirrhosis; however, significant hepatic decompensation (e.g., coagulopathy, encephalopathy) is atypical and should prompt evaluation for coincident chronic liver disease or drug-induced injury.

Complications arise from both renal and systemic immune pathophysiology. Progressive chronic kidney disease (CKD) develops in ~15–30% of untreated patients, with 5–10% progressing to end-stage kidney disease (ESKD) over 5–10 years—particularly in those with persistent high-level viremia, older age at onset, or MPGN histology. Thromboembolic events—including deep vein thrombosis, pulmonary embolism, and renal vein thrombosis—are significantly increased due to the nephrotic state (loss of antithrombin III, protein S, and plasminogen; elevated fibrinogen and platelet reactivity). Infections—especially spontaneous bacterial peritonitis, cellulitis, and pneumonia—are major causes of morbidity and mortality, driven by immunoglobulin loss, complement depletion, and impaired opsonization. Acute kidney injury may complicate intercurrent illness, NSAID use, or contrast exposure. Rarely, HBV-GN triggers autoimmune phenomena such as thyroiditis or cytopenias. Long-term complications also include cardiovascular disease accelerated by dyslipidemia, hypertension, and chronic inflammation.

Diagnosis relies on integration of serologic, urinary, histologic, and virologic data. Serologic testing must confirm chronic HBV infection: persistent HBsAg positivity (>6 months), detectable HBV DNA (typically >2,000 IU/mL), and frequently HBeAg positivity or precore/core promoter mutants. Anti-HBc IgG is invariably positive; anti-HBs is negative. Urinalysis reveals proteinuria (often nephrotic-range) and dysmorphic RBCs or RBC casts in active disease. Quantitative assessment includes 24-hour urine protein excretion or urine protein-to-creatinine ratio (UPCR >350 mg/mmol suggests nephrotic-range). Serum albumin, lipid panel, creatinine, eGFR, C3/C4 complement levels (often low in MPGN), and ANA/ANCA are essential. Renal biopsy remains the diagnostic gold standard: light microscopy shows characteristic patterns (e.g., diffuse capillary wall spikes and subepithelial deposits in MN; mesangial hypercellularity and double contours in MPGN); immunofluorescence demonstrates dominant granular capillary loop and/or mesangial staining for HBsAg (and often IgG, C3); electron microscopy confirms subepithelial (MN) or subendothelial/mesangial (MPGN) electron-dense deposits containing HBsAg. Viral antigens must be demonstrated in glomeruli—not merely circulating—to confirm causality.

Differential diagnosis is critical to avoid misattribution. Primary membranous nephropathy (anti-PLA2R– or anti-THSD7A–positive) lacks HBV serologic markers and shows no glomerular HBsAg deposition. Lupus nephritis presents with multi-system involvement (malar rash, photosensitivity, arthritis, cytopenias), positive ANA/dsDNA, and full-house immunofluorescence (IgG, IgA, IgM, C3, C1q). Post-infectious GN (e.g., post-streptococcal) follows a recent pharyngeal or skin infection, features low C3, and resolves spontaneously; HBV-GN is chronic and lacks antistreptolysin O elevation. Cryoglobulinemic GN (often HCV-associated) shows cryoprecipitates, low C4, and vasculitic lesions on biopsy. Idiopathic MPGN must be distinguished from HBV-GN via HBsAg staining and viral load quantification. Finally, drug-induced GN (e.g., NSAIDs, interferon-alpha) requires careful medication history—though interferon therapy itself may rarely unmask or exacerbate HBV-GN. Accurate differentiation guides antiviral therapy selection and avoids inappropriate immunosuppression, which may worsen HBV replication and accelerate hepatic or renal damage.

Hepatitis B virus-associated glomerulonephritis (HBV-GN) is an immune-complex–mediated renal disease predominantly affecting children and young adults in endemic HBV regions. It most commonly manifests as membranous nephropathy (MN), though membranoproliferative glomerulonephritis (MPGN) and IgA-dominant proliferative GN may also occur. Pathogenesis involves deposition of HBV antigens—particularly hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg)—within the glomerular basement membrane and mesangium, triggering complement activation and inflammatory injury. Diagnosis requires serologic confirmation of chronic HBV infection (HBsAg positivity ≥6 months), histopathologic evidence of GN on renal biopsy, and immunohistochemical or electron microscopic detection of HBV antigens in glomeruli. Treatment must simultaneously address viral replication and immune-mediated renal damage, with goals of achieving sustained virologic suppression, reducing proteinuria, preserving estimated glomerular filtration rate (eGFR), and preventing progression to end-stage kidney disease (ESKD).

Conservative management forms the cornerstone of early intervention and remains essential across all disease stages. Patients require strict avoidance of nephrotoxic agents—including NSAIDs, aminoglycosides, and contrast media—and rigorous control of modifiable risk factors. Blood pressure must be maintained ≤130/80 mmHg using renin-angiotensin-aldosterone system (RAAS) blockade: angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) are first-line, titrated to maximal tolerated doses to reduce intraglomerular hypertension and proteinuria. Dietary sodium restriction (<2 g/day) and moderate protein intake (0.8–1.0 g/kg/day) are recommended to mitigate edema and glomerular hyperfiltration. Lipid management targets LDL cholesterol <2.6 mmol/L; statins are preferred given their pleiotropic anti-inflammatory and antiproteinuric effects. Regular monitoring includes serum creatinine, eGFR, urinary protein-to-creatinine ratio (UPCR), HBV DNA quantification, HBeAg/anti-HBe serostatus, liver enzymes, and abdominal ultrasound every 3–6 months. Vaccination against hepatitis A, pneumococcus, and influenza is strongly advised.

Pharmacotherapy is stratified by disease severity, viral activity, and histologic subtype. For patients with low-level viremia (HBV DNA <2,000 IU/mL), normal ALT, and minimal proteinuria (<1 g/day), observation with close surveillance may suffice. However, persistent nephrotic-range proteinuria (>3.5 g/day), declining eGFR, or high HBV DNA (>20,000 IU/mL) warrants antiviral therapy. Nucleos(t)ide analogues (NAs) are first-line: entecavir (0.5 mg daily in nucleoside-naïve adults) or tenofovir disoproxil fumarate (TDF, 300 mg daily) or tenofovir alafenamide (TAF, 25 mg daily) are preferred due to high barrier to resistance and proven renal safety profiles—especially TAF, which achieves potent viral suppression with lower systemic exposure and reduced proximal tubular toxicity. Interferon-alpha (IFN-α) is rarely used in HBV-GN due to its proinflammatory effects and risk of exacerbating proteinuria or precipitating acute kidney injury; it may be considered only in select HBeAg-positive adolescents with preserved renal function and no contraindications, under strict nephrology-hepatology co-management. Immunosuppressants—including corticosteroids, cyclophosphamide, or calcineurin inhibitors—are generally contraindicated unless compelling evidence excludes active HBV replication (e.g., undetectable HBV DNA after prolonged NA therapy) and alternative diagnoses (e.g., primary MN) are ruled out. In rare refractory cases with severe crescentic GN or rapidly progressive decline, short-course pulse methylprednisolone (500–1000 mg IV × 3 days) followed by oral taper may be cautiously employed—but only after confirming virologic control and with concurrent NA escalation.

Surgical treatment has no definitive role in HBV-GN. Renal biopsy is diagnostic—not therapeutic—and performed percutaneously under ultrasound guidance with strict adherence to bleeding precautions (platelet count >100 × 10⁹/L, INR <1.5). Nephrectomy is never indicated for HBV-GN itself. In end-stage disease, kidney transplantation is feasible but requires meticulous pre-transplant virologic control: HBV DNA must be undetectable for ≥6 months on stable NA therapy, with anti-HBs titers ≥100 mIU/mL post-vaccination or hepatitis B immunoglobulin (HBIG) prophylaxis initiated perioperatively. Post-transplant, lifelong NA continuation is mandatory; TAF is favored over TDF to minimize bone and renal toxicity in transplant recipients.

China offers distinct advantages in HBV-GN management. First, nationwide integration of hepatology and nephrology services enables rapid multidisciplinary evaluation—many tertiary centers operate joint HBV-GN clinics with real-time access to liver elastography, quantitative HBsAg assays, and next-generation sequencing for HBV genotyping and resistance profiling. Second, China’s robust generic pharmaceutical industry ensures broad availability of high-quality, low-cost NAs (e.g., domestically manufactured entecavir and TAF), improving long-term adherence. Third, standardized national guidelines—such as the 2023 Chinese Society of Nephrology Consensus on Viral GN—emphasize biopsy-driven, individualized therapy and incorporate emerging biomarkers like urinary HBsAg quantification and podocyte-derived exosomal miRNAs for early response prediction. Fourth, large-scale prospective registries (e.g., the China HBV-GN Cohort Study) provide real-world evidence supporting earlier NA initiation and longer treatment duration (>3 years) for sustained remission. Finally, telemedicine platforms facilitate longitudinal follow-up in rural areas, with AI-assisted interpretation of urinalysis and UPCR trends enhancing early relapse detection.

Recovery and long-term prognosis depend critically on adherence and surveillance. Patients should understand that HBV-GN is typically indolent but potentially progressive over decades; complete clinical remission (UPCR <0.3 g/g and stable eGFR) occurs in ~60–70% of treated adults within 2–4 years, while partial remission (≥50% proteinuria reduction) is achieved in another 20%. Relapse risk remains elevated if NAs are discontinued prematurely—even after HBeAg seroconversion—thus indefinite therapy is standard. Lifestyle counseling emphasizes smoking cessation, regular aerobic exercise (150 min/week), and avoidance of herbal nephrotoxins (e.g., aristolochic acid-containing preparations). Psychological support is integral: depression and health-related anxiety are prevalent, particularly among young patients facing chronic dual-organ disease. Annual screening for hepatocellular carcinoma (abdominal ultrasound + AFP) and esophageal varices (if cirrhosis present) is mandatory. With comprehensive, coordinated care, 10-year renal survival exceeds 90%, underscoring that HBV-GN is a manageable chronic condition rather than an inevitable precursor to ESKD.